Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Unique Mechanism of Action Positions Plinabulin as a Preventive and Active Therapy in Breast Cancer, NSCLC

July 19th 2021

The highly differentiated mechanism of action of plinabulin, an investigational, first-in-class, selective immunomodulating microtubule binding agent, has positioned the drug as a potential preventive treatment for chemotherapy-induced neutropenia, as well as an anticancer agent in non–small cell lung cancer.

Atezolizumab/Bevacizumab Demonstrates Durable Efficacy in Advanced Malignant Peritoneal Mesothelioma

July 15th 2021

The combination of atezolizumab plus bevacizumab elicited encouraging, durable responses in patients with advanced malignant peritoneal mesothelioma, irrespective of tumor mutational burden and PD-L1 expression status.

Advances Propel Lung Cancer Paradigms Forward to Improved Outcomes and Quality of Life

July 15th 2021

Among a plethora of novel immunotherapeutic and targeted agents, the treatment landscapes for small cell lung cancer and non–small cell lung cancer have witnessed a rapid expansion that has led to improved survival and quality of life for patients, including a wider range of patients who harbor molecular abnormalities.

First-Line Therapy in ES SCLC: CASPIAN

July 15th 2021

Thoracic oncologist, Anne Chiang, MD, PhD, reviews the trial design and results of the CASPIAN trial and emphasizes implications for long-term benefit of combining platinum chemotherapy with durvalumab.

Implications of Novel NSCLC Targeted Therapies

July 15th 2021

An expert in non–small cell lung cancer (NSCLC) provides an overview of recent data presented at the American Society of Clinical Oncology 2021 annual meeting to treat MET exon 14 mutations.

Novel Therapies for NSCLC

July 15th 2021

Edward Kim, MD, MBA, summarizes recent data for HER2-mutated in non–small cell lung cancer (NSCLC) presented at the American Society of Clinical Oncology 2021 annual meeting.

First-Line Therapy in ES SCLC: IMpower133

July 15th 2021

Stephen Liu, MD guides a discussion on recent updates on IO+chemotherapy combinations in extensive-stage small cell lung cancer by reviewing data from the phase 3 IMpower133 l trial of carboplatin/etoposide/atezolizumab.

Amivantamab Paves a New Treatment Path for Patients With EGFR Exon 20–Mutant NSCLC

July 14th 2021

Amivantamab ushers in a new era of targeted treatment for patients with locally advanced or metastatic non–small cell lung cancer with EGFR exon 20 insertion mutations.

Immune-Related Adverse Events in NSCLC

July 14th 2021

Recommendations for managing immune-related adverse events associated with checkpoint inhibitors used to treat stage IV non–small cell lung cancer.

Frontline Treatment of Stage IV NSCLC: Biomarkers

July 14th 2021

Martin Dietrich, MD, PhD, shares his thoughts on PD-L1 status, tumor mutational burden, and other predictive and prognostic biomarkers when making treatment decisions for patients with stage IV non–small cell lung cancer.

Rapid Readouts: Safety and Efficacy of Pralsetinib in Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer: Update from the ARROW trial

July 13th 2021

Stephen V. Liu, MD, presents data from the 2021 American Society of Clinical Oncology annual meeting on the updated results from the ARROW trial of pralsetinib in patients with RET fusion-positive non-small cell lung cancer.

NSCLC: FLAURA Trial Results

July 8th 2021

Edward Kim, MD, briefly summarizes results from the FLAURA trial in the treatment of previously untreated EGFR+ advanced non–small cell lung cancer (NSCLC).

Updates in ALK-Positive Non–Small Cell Lung Cancer

July 8th 2021

On May 4, 2021, a select group of oncologists participated in a virtual workshop to discuss the treatment landscape and management of patients with ALK-positive NSCLC. This article summarizes key data about ALK-positive NSCLC as well as insights from stakeholder discussions regarding this topic.

First Generation TKIs in NSCLC

July 8th 2021

Melissa Johnson, MD, provides an overview of other first generation TKIs for the treatment of non–small cell lung cancer (NSCLC) in the adjuvant setting.

EGFR+ NSCLC: Advice for Community Oncologists

July 8th 2021

A panel of experts in thoracic oncology concludes the discussion by emphasizing the importance of conducting reflex molecular testing, considering systemic therapy in all patients, and utilizing shared decision-making models.

Potential Treatments for Uncommon EGFR Mutations in NSCLC

July 8th 2021

A key opinion leader in lung cancer, Solange Peters, MD, PhD, provides a review of treatments under investigation for uncommon mutations in NSCLC: mobocertinib, amivantamab, poziotinib, and neratinib.

Treatment Algorithms and Resistance Mechanisms in NSCLC

July 8th 2021

Gary Doherty, MRCP, PhD, Solange Peters, MD, PhD, and Christian Grohé, MD, discuss approaches to selecting or switching treatment based on molecular testing for biomarkers and pathways of resistance.

Frontline Treatment Decisions for Stage IV NSCLC

July 7th 2021

Considerations for selecting frontline therapy for metastatic non–small cell lung cancer based on various new data and treatment approvals in the field of immunotherapy.

Frontline Treatment of Stage IV NSCLC: IPI/NIVO

July 7th 2021

Neal Edward Ready, MD, PhD, describes which patients with stage IV non–small cell lung cancer may benefit from the combination of ipilimumab and nivolumab in the frontline treatment setting.

TIL Therapy LN-145 Elicits 21.4% ORR in Previously Treated Metastatic NSCLC

July 7th 2021

The tumor-infiltrating lymphocyte therapy LN-145 was found to induce an objective response rate of 21.4% in patients with advanced or metastatic non–small cell lung cancer who had progressed following systemic therapy.